Small-molecule tyrosine kinase inhibitors targeting oncogenic driver mutations (such as EGFR, ALK, ROS1 and BRAF (1)) have fundamentally changed the treatment paradigm for non-small cell lung cancer (NSCLC). The gene discussed is ALK; the disease is non-small cell lung carcinoma.